Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06318871 · ClinicalTrials.gov registry record · Early Phase 1
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
A Early Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT06318871: Recruiting Early Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma, sponsored by Dana-Farber Cancer Institute.
NCT06318871 is a Early Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06318871, a Early Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and treat curtained advanced cancers, combined with low dose IL-2, which is a cytokine that activates immune cells, in advanced clear cell renal cell carcinoma and urothelial carcinoma. Names of the study therapies involved in this study are/is: * CIML NK cell therapy (a NK cell therapy) * IL-2 (a type of cytokine)
Primary Outcome
Feasibility is defined as the ability to collect cells, generate product, and administer CIML NK plus 6-day maintenance culture cells to participants. FFR is defined as the proportion pf participants that do not achieve the feasibility during the maintenance phase.
Conditions Studied
Interventions
- BIOLOGICAL Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
- DRUG Interleukin-2 (IL-2)
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2031-07-28 |
| Phase | Early Phase 1 |
What NCT06318871 shows while recruiting
NCT06318871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cytokine Induced Memory-like Natural Killer (CIML NK) Cells is the first listed.
NCT06318871 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06318871 about?
NCT06318871 is a clinical study titled "Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma". The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and trea...
What is the current status of trial NCT06318871?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2024-08-28. Estimated completion is 2031-07-28.
What conditions does trial NCT06318871 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma, Renal Carcinoma, Translocation Renal Cell Carcinoma.
What interventions are being tested in trial NCT06318871?
The interventions under investigation include: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells (BIOLOGICAL), Interleukin-2 (IL-2) (DRUG).
Who is sponsoring clinical trial NCT06318871?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06318871 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06318871's enrollment target sits among peer trials
10 119th of 121 higher than 2 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
RECRUITING · Early Phase 1
-
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
RECRUITING · Early Phase 1
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
PET/MR for Characterization of Renal Masses (RMs)
RECRUITING
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI